Mycophenolate vs Azathioprin in Autoimmune Hepatitis

Rigshospitalet

Status and phase: Completed; Phase 4

Conditions: Autoimmune Hepatitis

Treatments: Drug: Treatment with azathioprin; Drug: Treatment with mycophenolat mofetil

Study type: Interventional

Funder types: Other

Identifiers

NCT00687180

MMF vs Imurel

Details and patient eligibility

About

A study with 20 de novo patients with autoimmune hepatitis, 10 receiving azathioprin and 10 receiving mycophenolat mofetil.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• De novo autoimmune hepatitis
• Consent

Exclusion criteria

• age below 18
• pregnancy

Trial design

0 participants in 2 patient groups

I

Active Comparator group

Description:

MMF

Treatment:

Drug: Treatment with mycophenolat mofetil

II

Active Comparator group

Treatment:

Drug: Treatment with azathioprin